Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Jan;10(1):79-82.
doi: 10.21037/jtd.2017.12.15.

The significance of pathological extracapsular vs. intracapsular lymph node involvement in patients with resectable esophageal cancer after neoadjuvant therapy

Puja Gaur Khaitan  1 , Thomas J Watson  1
Affiliations
Editorial

The significance of pathological extracapsular vs. intracapsular lymph node involvement in patients with resectable esophageal cancer after neoadjuvant therapy

Puja Gaur Khaitan et al. J Thorac Dis. 2018 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Treatment schema for patients diagnosed with resectable, localized esophageal cancer. In our current practice, any patient with ypTxN+ pathology gets treated with adjuvant therapy. Controversy exists about who constitutes this node-positive cohort: should all patients with extra- or intracapsular invasion (IC-LNI and EC-LNI) get treated with adjuvant therapy, and what about patients with non-viable tumor cells in their lymph nodes? CRT, chemoradiation therapy; pCR, pathologic complete response.
See this image and copyright information in PMC

Comment on

References

    1. Ajani JA, D'Amico TA, Almhanna K, et al. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw 2015;13:194-227. 10.6004/jnccn.2015.0028 - DOI - PubMed
    1. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681-92. 10.1016/S1470-2045(11)70142-5 - DOI - PubMed
    1. Burt BM, Groth SS, Sada YH, et al. Utility of adjuvant chemotherapy After neoadjuvant chemoradiation and esophagectomy for esophageal cancer. Ann Surg 2017;266:297-304. 10.1097/SLA.0000000000001954 - DOI - PubMed
    1. Lagarde SM, ten Kate FJ, de Boer DJ, et al. Extracapsular lymph node involvement in node-positive patients with adenocarcinoma of the distal esophagus or gastroesophageal junction. Am J Surg Path 2006;30:171-6. 10.1097/01.pas.0000189182.92815.12 - DOI - PubMed
    1. Lerut T, Coosemans W, Decker G, et al. Extracapsular lymph node involvement is a negative prognostic factor in T3 adenocarcinoma of the distal esophagus and gastroesophageal junction. J Thorac Cardiovasc Surg 2003;126:1121-8. 10.1016/S0022-5223(03)00941-3 - DOI - PubMed

LinkOut - more resources